Pham Cam Phuong1, Nguyen Quang Hung2, Tran Bao Ngoc3, Dirk Rades4,5, Mai Trong Khoa2,5. 1. The Nuclear Medicine and Oncology Center, Bach Mai Hospital, Hanoi, Vietnam phamcamphuong@gmail.com. 2. The Nuclear Medicine and Oncology Center, Bach Mai Hospital, Hanoi, Vietnam. 3. Department of Oncology, Thai Nguyen University of Medicine and Pharmacy, Thai Nguyen, Vietnam. 4. Department of Radiation Oncology, University of Lübeck, Lübeck, Germany. 5. Department of Nuclear Medicine, Ha Noi Medical University, Hanoi, Vietnam.
Abstract
AIM: To evaluate the role of rotating gamma system (RGS) radiosurgery for low-grade brainstem gliomas. PATIENTS AND METHODS: Thirty-seven patients undergoing RGS radiosurgery at the Bach Mai Hospital Hanoi for low-grade brainstem glioma were included in this prospective interventional study. The median RGS dose was 12 Gy (range=8-16 Gy). Endpoints included response to RGS radiosurgery given as change in glioma size (maximum diameter), survival and adverse events. Follow-up was performed for 36 months. Three dose-groups (<13, 13-14 and >14 Gy) were compared for survival. RESULTS: Mean glioma size decreased from 1.87 cm before RGS irradiation to 1.15 cm at 36 months. Mean survival was 39.5 months. Mean survival after <13, 13-14 and >14 Gy were 22.7, 66.7 and 49 months, respectively (p<0.05). Adverse events, mainly reduced appetite, sleep disturbances, headache and edema, were not associated with RGS dose and were easily managed. CONCLUSION: RGS radiosurgery led to promising results with acceptable toxicity in patients with low-grade brainstem gliomas. Copyright
AIM: To evaluate the role of rotating gamma system (RGS) radiosurgery for low-grade brainstem gliomas. PATIENTS AND METHODS: Thirty-seven patients undergoing RGS radiosurgery at the Bach Mai Hospital Hanoi for low-grade brainstem glioma were included in this prospective interventional study. The median RGS dose was 12 Gy (range=8-16 Gy). Endpoints included response to RGS radiosurgery given as change in glioma size (maximum diameter), survival and adverse events. Follow-up was performed for 36 months. Three dose-groups (<13, 13-14 and >14 Gy) were compared for survival. RESULTS: Mean glioma size decreased from 1.87 cm before RGS irradiation to 1.15 cm at 36 months. Mean survival was 39.5 months. Mean survival after <13, 13-14 and >14 Gy were 22.7, 66.7 and 49 months, respectively (p<0.05). Adverse events, mainly reduced appetite, sleep disturbances, headache and edema, were not associated with RGS dose and were easily managed. CONCLUSION: RGS radiosurgery led to promising results with acceptable toxicity in patients with low-grade brainstem gliomas. Copyright
Authors: David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison Journal: Acta Neuropathol Date: 2016-05-09 Impact factor: 17.088
Authors: S J Goetsch; B D Murphy; R Schmidt; J Micka; L De Werd; Y Chen; S Shockley Journal: Int J Radiat Oncol Biol Phys Date: 1999-02-01 Impact factor: 7.038
Authors: Santosh Kesari; Ryung S Kim; Vassilios Markos; Jan Drappatz; Patrick Y Wen; Amy A Pruitt Journal: J Neurooncol Date: 2008-06 Impact factor: 4.130